IF 52.7 Literature Sharing from ELK Biotechnology - (주)코아사이언스

www.elkbiotech.com                                                         ELK Biotechnology 

IF 52.7 Publication Sharing

 

We are proud to announce that ELK Biotech's high-specificity ELISA kits have been cited in a high-impact study published in Signal Transduction and Targeted Therapy (IF 52.7), a Nature Portfolio journal

 

Literature title: ​Inhibin beta A drives colorectal cancer progression through macrophage M2 polarization and mitochondria-dependent ferroptosis suppression Impact Factor: 52.7 Journal: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-025-02518-y

Key Findings Inhibin βA promotes M2 macrophage polarization in the colorectal cancer microenvironment Suppresses mitochondria-dependent ferroptosis in cancer cells, enhancing tumor survival Identifies a novel signaling pathway linking immune modulation and cell death resistance Potential therapeutic target for colorectal cancer treatment

ELK Biotechnology Products Used  

The following ELK products were utilized in this groundbreaking research:

Human IL-10 ELISA Kit (ELK1142)
Human ARG1 ELISA Kit (ELK1790)
Human TGF-β1 ELISA Kit (ELK1185)
Human VEGFA ELISA Kit (ELK1129)

코아사이언스 coresciences Korea ELK Biotechnology CO.,LTD ELK (Wuhan) Biotechnology CO.,Ltd. 한국 대리점 ELISA antibody 항체 면역학 연구 세포배양 분자생물학 시약